cyrilzakka/clinical-trials huggingface dataset:
Impact of Regular Consumption of Eggs and Nutrients Fortified Eggs on Eczema Condition in Singapore Individuals

The study aims to assess the effects of daily consumption of nutrients-fortified eggs on eczema condition in Singapore individuals with eczema. The investigators hypothesize that egg consumption will improve eczema condition and nutrients fortified egg consumption will improve further improvements when compared to standard egg consumption in individuals with eczema

This is a double-blind, randomized, parallel study and all subjects will complete a 12-week study period. Subjects will be tasked to consume nutrients-fortified eggs and regular eggs daily for 12 weeks. After which, subjects are assessed for changes in carotenoid status, antioxidant and anti-inflammatory biomarkers, skin and eye health measurements, and other biomarkers of health.

Eligibility Criteria:
Inclusion Criteria:

1. English-literate and able to give informed consent in English
2. Male and female participants, aged between 21 and 59 inclusive
3. Healthy individuals with no underlying condition or on regular medication
4. BMI between 18.5-25 kg/m2
5. Mild to moderate severity of eczema, which will also be determined using our questionnaires during the screening visit

Exclusion Criteria:

1. Significant change in body weight (3 kg or more) in the past 3 months
2. Significant exercise pattern over the past 3 months defined as high-intensity exercise of more than 3 hours per week
3. Known food allergy to eggs
4. Taking dietary supplements which may impact the study results
5. Having gastrointestinal disorders not suitable for the study
6. Current smokers
7. Consumes more than 2 alcoholic drinks per day i.e. one drink is defined as either 150ml of wine, 340ml of beer/cider, or 45ml of distilled spirit
8. Taking lipid-lowering and blood pressure-controlling medications for less than 3 years
9. Pregnant or lactating women, or planning to conceive in the next 6 months
10. Unwilling to stop the medication of eczema during the study, either topical creams or oral medications
11. Hierarchical link (professional and familial ties) with the research team members
12. Participating in another clinical study
13. Having blindness in one eye or more, eye diseases, retinal/lens/optical nerve surgery, or other eye conditions that may impact the study results
14. Low-quality macular pigment optical density results were determined during the screening visit.
Insulin Variance Throughout the Day

This study is designed to determine whether the sensitivity of a participant's insulin varies from the morning to the evening.

Study visit 1: about 16 hours - The participant will arrive to the visit fasting.

The participant will have an oral glucose tolerance test which takes about 3 ½ hours.

An IV line will be placed in the participant's arm vein for blood draw purposes and will remain there throughout the testing. A blood sample will be drawn 15 minutes and just before the participant will drink a sugar solution consisting of 75 grams of glucose. Blood will be drawn at specific times after the participant consumes the drink.

The participant will have a second oral glucose tolerance test which takes about 3 ½ hours. An IV line will be placed in the participant's arm vein for blood draw purposes and will remain there throughout the testing. A blood sample will be drawn 15 minutes and just before the participant drinks a sugar solution. Blood will be drawn at specific times after the participant consumes the drink.

Eligibility Criteria:
Inclusion Criteria:

* Are a healthy male or female
* Have a fasting blood sugar that is between normal and diabetes.
* Are between 18 and 70 years of age, inclusive.

Exclusion Criteria:

* Are pregnant or breast-feeding a child
* Take a medication for diabetes
* Take a medication like cortisone that can change your blood sugar.
* Take a medication chronically that has not been at a stable dose for at least 1 month
* Take medication for psychosis that is known to change timing in the day - night cycle
Comparison of Multi-point Pacing and Conventional CRT Through Non-invasive Hemodynamics Measurement and Global Longitudinal Strain Assessment

Pilot, perspective, multi-center non-randomized study comparing Multi-point pacing and conventional CRT through non-invasive hemodynamics measurement and Global Longitudinal Strain assessment


Eligibility Criteria:
Inclusion Criteria:

* Recent or scheduled implantation of CRT-D system with quadripolar lead and MPP technology in patient with indications to CRT according to current guidelines

Exclusion Criteria:

* Patients in Atrial Tachycardia (AT) or Atrial Fibrillation (AF) at the time of the enrollment or with persistent or long-standing persistent/chronic AF
* NYHA IV patients
* Right Bundle Branch Block
Effects of Remimazolam and Propofol on Anesthesia Induction

The patients with diabetes who underwent laparoscopic cholecystectomy in the general surgery department of the Second Hospital of Shanxi Medical University were selected. The patients who were induced by remimazolam were included in the experimental group, and the patients who were induced by propofol were included in the control group. All the selected patients had no intimate relationship. The differences of blood pressure, heart rate and heart rate variability (HRV) between the experimental group and the control group were observed. According to the literature, it is speculated that the changes of blood pressure, heart rate and HRV indexes in the experimental group are smaller than those in the control group, and the difference is statistically significant.


Eligibility Criteria:
Inclusion Criteria:

* Diagnosed as type 2 diabetes according to the "Chinese Guidelines for the Prevention and Treatment of Type 2 diabetes 2020"
* ASA II or III

Exclusion Criteria:

* People who are allergic to Remimazolam
* It is estimated that patients with difficulty in tracheal intubation (poor head and neck mobility, history of airway surgery, history of OSAHS, nail to chin distance\<6cm, Malampati grade 3 and above, mouth opening\<2.5cm, obesity (BMI\>30kg · m-2), etc
* Hypertension (clinically diagnosed as hypertension)
* Patients with coronary heart disease (with typical symptoms of angina pectoris and exclusion of aortic valve disease, clear history of old myocardial infarction, clear history of acute myocardial infarction, coronary stenosis greater than or equal to 70% found by CAG)
* Patients with arrhythmia, heart failure, renal failure, and recently taking cardiovascular active drugs
* Endocrine diseases such as hyperthyroidism and pheochromocytoma that may affect the level of body hemodynamics
* Ketoacidosis and lactic acidosis
* Patients with long-term use of sedatives or antidepressants or a history of alcoholism or drug dependence
* Asthma or reactive airway disease
* Patients with myasthenia gravis and cognitive dysfunction cannot cooperate with this study
Feasibility of Teleyoga for Treatment of Lyme Disease

Primary Aims: Modify an existing teleyoga intervention to use with Lyme disease (LD) patients and address the technical challenges of at-home teleyoga

Participants with symptoms of Lyme disease (n=15) will participate individually in a weekly tele-yoga class using an iPad loaned by the study. Participants will choose where to attend these remote treatment sessions. Yoga treatment will last 12 weeks. Participants' subjective pain will be rated at baseline and end-of-treatment using a standard pain scale. Also assessed will be participant adherence to study protocol by tracking treatment attendance

Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of probable Lyme disease
* Has not begun new pain medications or other treatments in the last month
* English literacy
* Wireless internet connection at home

Exclusion Criteria:

* Participation in another concurrent clinical trial
* Back surgery within the last 12 months
* Unstable, coexisting mental illness or psychiatric condition
* Active, current suicidal intent or plan
* Attended or practiced yoga ≥ 1 x in the past 12 months
Spinal Manipulation and Spinal Mobilization Effects in Participants With and Without Back Pain

The objective of the present study is to compare the neuromechanical responses to spinal manipulation and spinal mobilization in participants with chronic nonspecific middle back pain.

Although evidences suggest a similar effectiveness of spinal manipulation and spinal mobilization, there is no study that compares the neuromechanical effects of these manual therapies in a experimental context and with the standardization of both interventions. Therefore, the objective of the present study is to compare the neuromechanical responses to spinal manipulation (low-amplitude and high-velocity dynamic thrust) and spinal mobilization (repetitions of a low-amplitude and low-velocity nonthrust movement) in participants with and without chronic nonspecific back pain.

Eligibility Criteria:
Inclusion Criteria:

* presenting or not a history of chronic nonspecific back pain

Exclusion Criteria:

* History of back trauma or surgery
* Severe osteoarthritis
* Inflammatory arthritis
* Vascular conditions
* Contraindication to the use of spinal manipulation or spinal mobilization
* Pregnancy
* Scoliosis
A Comparison of Post-Sternotomy Dressings

The purpose of this study was to determine which of three types of dressings, a dry sterile dressing, a metallic silver dressing or an ionic silver dressing provided better patient outcomes for the post-sternotomy cardiac surgery patient population. In this prospective, randomized controlled trial, the hypothesis was that subjects who received either of the silver impregnated dressings would have better outcomes (better wound healing, less discomfort, and less incidence of infection). Investigators also evaluated dressing factors such as adherence, time for application and ease of use.

No other information included.

Eligibility Criteria:
Inclusion Criteria:

* Adult (at least 21 years of age) inpatients awaiting cardiac surgery or outpatients seen in the pre-surgical testing area prior to admission for surgery
* Having surgery at the study setting
* English-speaking
* Able to understand and give consent
* Had the approval of their cardiothoracic surgeon to participate
* Had no known sensitivity to silver
* Had no known sensitivity to alginates

Exclusion Criteria:

* Known sensitivity to silver
* Known sensitivity to alginates
Graft Patency Analysis of the Right Coronary Artery System

The ideal grafts for the right coronary artery system in coronary artery bypass surgery remain controversial. The objective of this study is to compare the long-term patency of a right gastroepiploic artery and a saphenous vein graft used for revascularization of the right coronary artery system in off pump coronary artery bypass surgery and to analyze the long-term clinical outcomes.

Total 224 patients will be enrolled according to the randomization protocol.

Check list

1. Laboratories
2. Quantitative coronary analysis (preoperative)
3. Major adverse cardiac and cerebrovascular event
4. coronary CT (coronary angiography if needed) at discharge, 1, 5, 10 years postoperatively
5. Echocardiogram

5. Cardiac enzyme

The ideal bypass conduit for the right coronary artery remains a subject of intense controversy. A variety of grafts and configurations are used: the right gastroepiploic artery,the right internal thoracic artery in situ or in a Y-graft configuration,the free radial artery implanted into the aorta or the left internal thoracic artery, and the saphenous vein graft. The influence of the type of graft to the right coronary artery system on clinical results remains poorly documented, and the complementary conduit of choice to this system has yet to be determined. No superior long-term patency rate for any of these grafts to the RCA has been clearly established. We have used a saphenous vein and a right gastroepiploic artery for the right coronary artery system.

Eligibility Criteria:
Inclusion Criteria:

* Angiographic evidence of severe coronary stenosis on the right coronary territory
* Elective surgery
* Isolated off pump CABG
* Age \< 75 years and life expectancy \> 5 years
* Preoperative RGEA diameter \> 1.5mm
* Normal left ventricular function

Exclusion Criteria:

* History of upper abdomen surgery
* History of upper GI bleeding
* Active gastric or duodenal ulcer
* Body mass index \> 35kg/m2
* Redo surgery
* Presence of varicose vein
* Contraindication for CABG such as malignancy or liver cirrhosis
* Other configuration than RGEA to RCA territory or SVG to RCA territory
Factors Affecting Outcome of Vestibular Rehabilitation

This is an observational longitudinal study to investigate if negative illness perceptions predict less improvement in dizziness handicap following vestibular rehabilitation. Consecutive patients (n=260) who enter the vestibular rehabilitation programme at Guy's Hospital, London will be included. Questionnaires will be conducted immediately before, and after their final treatment. The main outcome will be the Dizziness Handicap Inventory after rehabilitation.

The aim of this longitudinal study is to investigate whether illness perceptions predict dizziness handicap following a treatment as usual 8-week vestibular rehabilitation programme in patients with chronic vertigo and dizziness.

Participants will be recruited consecutively from patients attending the dizziness and balance exercise programme at Guys \& St Thomas' NHS Foundation Trust. Consenting patients will complete the following questionnaires before and after rehabilitation:

1. The Dizziness Handicap Inventory (DHI)
2. The Illness Perceptions Questionnaire - Revised (IPQ-R)
3. The Patient Health Questionnaire Anxiety and Depression Scale (PHQ-ADS)

The Dizziness Handicap Inventory (DHI) at discharge will be the dependent variable. We will also demographic data including age, gender, and illness type.

Eligibility Criteria:
Inclusion Criteria:

* are aged above 18 years old and are enrolled onto the vestibular rehabilitation programme due to chronic dizziness

Exclusion Criteria:

* Patients will be excluded if they have evidence of central nervous system disorders or cannot speak English.
Spectroscopy for Diagnostic Assessment of Oral Mucosal Lesions

The goal of this clinical research study is to test a new way to look for cancer and pre-cancerous tissue changes inside the mouth.

Abnormal-looking areas (lesions) inside the mouth may be a sign of cancer or changes that may lead to cancer. These lesions may need to be removed. Researchers are looking for a practical way to tell early on whether these lesions are cancer or may become cancer. This study will test a technique called fluorescence spectroscopy, which is under research in this study.

Each patient may have 1 to 5 lesions and several normal-looking areas inside the mouth exposed to a beam of light. The exposed tissues may emit very small amounts of light called fluorescence. This light is not seen by the eye but is detected by a computer. The small areas exposed to the light beam may then be removed.

The patients who need surgery may have the small tested areas removed when the lesions are surgically removed. A small sample from a normal-looking area may also be removed during surgery. Patients who do not need surgery may simply have small samples taken from the lesions and a normal-looking area in the clinic rather than in the operating room. The tissues will be looked at under a microscope to see whether they are cancerous. These results will be compared with the spectroscopy results.

If you are scheduled to participate in another MD Anderson study, Protocol 2008-0137 Entitled, "Phase Ib Study of Erlotinib Prior to Surgery in Patients with Head and Neck Cancer" (Study Chair: Dr. William William), some of your collected tissue samples may be shared with Dr. William for use on 2008-0137.

This is an investigational study. About 395 patients will be consented and screened for this study, with about 381 to take full part in this study. All will be treated at MD Anderson.

Eligibility Criteria:
Inclusion Criteria:

1. Any person 18 years of age or older with a lesion of the oral mucosa. Persons with changes in existing lesions or those who develop new lesions can be re-evaluated, but it is not required.

Exclusion Criteria:

NA
A Study of Adjunctive Aripiprazole in Patients With Major Depressive Disorder

This trial is a 14 week, randomized, double-blind, placebo controlled study, to assess the safety and efficacy of aripiprazole as adjunctive treatment to an ongoing antidepressant treatment in patients with Major Depressive Disorder.


Eligibility Criteria:
Inclusion Criteria:

* Men and women, 18-65 years old
* Experienced a Major Depressive Disorder with the current episode of minimally 8 weeks in duration.
* Treatment history of an inadequate response to at least one and no more than three antidepressants.
A Study of Epoetin Beta Treatment in Anemic Participants With Myelodysplastic Syndrome (MDS)

This is a Phase IV, prospective, multi-center, open-label study to assess the effectiveness and safety profile of epoetin beta (Recormon®) for treatment of symptomatic anemia in adult participants associated with low/intermediate-1-risk MDS. After screening, eligible participants will be treated with epoetin beta as recommended in the approved label and international guidelines for the use of epoetin in MDS participants and the dosage will be adjusted on the basis of erythroid response.


Eligibility Criteria:
Inclusion Criteria:

* Adult participants with low or intermediate-1 risk MDS
* No previous treatment with hematopoietic growth factors within 3 months prior to screening
* Symptomatic anemia (hemoglobin \<10 g/dL) as determined by investigator
* Serum erythropoietin \<500 milliunits/milliliter (mU/mL) within 14 days prior to the first dose of study treatment
* Require no red blood cell transfusion or dependent on \<4 units within 8 weeks prior to screening
* Clinically stable for at least 1 month prior to entry into the study
* For female participants of childbearing potential and male participants with partners of childbearing potential, agreement (by participants and/or partner) to use highly effective form(s) of contraception

Exclusion Criteria:

* Contraindications and/or known hypersensitivity to the active substance and/or any of the excipients of epoetin beta treatment
* Poorly controlled hypertension as assessed by the investigator
* History of Acute Myeloid Leukemia (AML) or high risk for AML
* Administration of another investigational drug within 1 month before screening or planned during the study period
* Previously documented evidence of Pure Red Cell Aplasia (PRCA)
Comparing Electrical Impedance Tomography to Computed Tomographic Angiography

The study aim is to determine whether electrical impedance tomography (EIT) is equivalent in the detection of pulmomary emboli compared to Computed Tomographic Angiography (CTA). EIT is a non-invasive, non-ionizing functional imaging technique that can be performed at bedside. Electrical impedance tomography data will be collected on individuals undergoing a CTA scan of the chest at Medical Center of the Rockies (MCR). The primary outcome measure is to assess whether assessment by CTA corresponds with EIT in detection of pulmonary emboli. The study will include up to 63 participants. EIT data will be collected for up to 20 minutes during tidal breathing and for approximately five to ten seconds during breath-holding.


Eligibility Criteria:
Inclusion Criteria:

* 18 years of age or older
* Undergoing a CTA of the chest at MCR

Exclusion Criteria:

* Under 18 years of age
* Body mass index (BMI) \> 30
* Individuals with known thoracic metal implants or devices, such as pacemakers (internal and external), staples, or spinal and rib hardware
* Individuals deemed by the research team as too unstable to safely apply the EIT belt, such as hemodynamic or respiratory instability (e.g., intubated patients), and individuals with unstable spinal injuries
* Open wounds at the site of electrode belt application
Decentralization of Hepatitis B Care in Sub-Saharan Africa: a Pilot Program in Ethiopia

The goal of this observational study is to study models of care for decentralized hepatitis B treatment in Ethiopia.

Three different models of decentralized HBV care (standard model, simplified model, test-and-treat model) will be implemented at primary hospitals or health clinics in Ethiopia. Treatment will be given for free to patients who meet the treatment criteria. We will compare clinical outcome, laboratory outcomes and programmatic outcome measures between the 3 models.

Chronic hepatitis B (CHB) is a major health problem globally, and in Ethiopia 5-10 % of the general population are infected with hepatitis B. In the absence of treatment, 15-40 % of these will die from its complications. Antiviral therapy effectively prevents disease progression and death in CHB. However, In low-income countries antiviral treatment is rarely available due to complex treatment guidelines, poor laboratory capacity, restrictions on antiviral treatment and lack of public funding.

In 2015, we set up a pilot treatment program for CHB at a tertiary hospital in Addis Ababa, Ethiopia. In 2021/22, this program was extended to four regional secondary hospitals to study simplified CHB care in a low-income country. With the present study we aim to decentralize CHB therapy to rural settings, which will be essential to achieve universal access to antiviral therapy in Africa. We will study different treatment models, each of which has its theoretical pros and cons: i) standard model ("treat only if..."), ii) inclusive model ("treat all except..."), and iii) test-and-treat ("treat all"). The primary endpoint will be death or liver decompensation, and secondary endpoints will be programmatic and laboratory success indicators. Moreover, we will study the cost-effectiveness of these decentralized models and compare with the tertiary/secondary hospital-based model.

Implementation research, such as our study, is of vital importance to respond to the research gaps identified by the World Health Organization in hepatitis B care. Our study is expected to directly inform international hepatitis B guidelines and will be a major contribution to the efforts to eliminate viral hepatitis as a public health threat by 2030.

Eligibility Criteria:
Inclusion Criteria:

* Adult (at least 18 years of age) who is HBsAg positive.

Exclusion Criteria:

* Below 18 years of age.
* Negative HBsAg rapid test at screening visit.
* Other disease with short life expectancy (disseminated cancer etc.)